International agenda
The international agenda describes the work of the National Health Care Institute in the international field. We collaborate with several countries in an increasing number of international activities. Collaboration strengthens us as a country, and allows us to learn from each other. The agenda includes our perspectives on relevant topics and information about our national activities.
International agenda: overview of the National Health Care Institute's international tasks
The Dutch healthcare system is influenced by international developments. That is why the National Health Care Institute operates at an international level. The international agenda outlines which international developments are relevant for us and shows the developments we are actively involved in.
Targets of the International Agenda 2024/2025
The international agenda sets out relevant topics and international activities for 2024 and 2025. It also describes the position of the National Health Care Institute on these relevant topics. The targets for 2024 and 2025 are:
- We collaborate strategically with other countries in the area of Health Technology Assessment (HTA). HTA is the evaluation of medicines and medical technology. Our strategic partnerships are focused on this, especially for the EU HTAR. In addition, in the field of HTA we also collaborate with the Heads of Agencies Group (HAG), the Beneluxa initiative and the International Grade Working Group. We also collaborate within the International Horizon Scanning Initiative (IHSI) on topics related to the horizon scanning of medicinal products. We are exploring the possibilities of extending this collaboration to medical technology.
- We are looking into the possible effects of the European Health Data Space (EHDS) on the Dutch healthcare system and the activities of the National Health Care Institute. We will investigate the impact of the EHDS and how we can prepare for it.
- We are focussing on possible international collaborations for quality of care.
- We are examining the revision of EU pharmaceutical legislation. This can have an impact on the affordability of care, including orphan drugs and personalised medicine. Personalised medicine aims to tailor medical treatments and medication specifically to the characteristics of an individual patient.
This is a summary of the original report of the International Agenda.